Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr-May:240:108044.
doi: 10.1016/j.rmed.2025.108044. Epub 2025 Mar 14.

Circulating CC16, immune response to Mycoplasma pneumoniae and lung function: a population-based, multi-cohort study

Alane Blythe C Dy  1 , Nipasiri Voraphani  2 , Amber Spangenberg  2 , Steven A Belinsky  3 , Maria A Picchi  3 , Erik Melén  4 , Inger Kull  4 , Angela Simpson  5 , Clare Murray  5 , Marilyn Halonen  6 , Julie G Ledford  7 , Stefano Guerra  8
Affiliations

Circulating CC16, immune response to Mycoplasma pneumoniae and lung function: a population-based, multi-cohort study

Alane Blythe C Dy et al. Respir Med. 2025 Apr-May.

Abstract

Background: Sufficient levels of club cell secretory protein (CC16) are essential to protect against lung function impairments. Experimental studies have demonstrated that CC16 modulates inflammatory responses and protects against airway hyperresponsiveness following Mycoplasma pneumoniae (Mp) infection. Individuals with asthma have low CC16 levels and increased susceptibility to Mp infection. Here we determine whether low CC16 and Mp seropositivity have combined effects on lung function deficits predisposing to airflow limitation, particularly in asthma.

Methods: Serum levels of CC16 and IgG antibodies against Mp (MpIgG) were measured in adult participants from cohorts BAMSE, MAAS, LSC, and TESAOD. Participants were then stratified into four groups: normal CC16/MpIgG-, normal CC16/MpIgG+, low CC16/MpIgG-, low CC16/MpIgG+. Associations between these groups and lung function (FEV1 and FEV1/FVC) were assessed by linear regression, adjusting for covariates. Meta-analyzed estimates were calculated.

Results: Low CC16 was associated with decreased lung function in the total population, but no combined effects of CC16 and MpIgG were observed. Among asthmatic participants, the low CC16/MpIgG + group had remarkably lower FEV1/FVC z-scores (-0.84, CI: 1.29, -0.38) compared to the reference group, and Mp seropositivity was associated with significant deficits in FEV1/FVC z-scores among those with low CC16 (-0.60, CI: 1.08, -0.12), but not among those with normal CC16 (-0.10, CI: 0.56, 0.36).

Conclusion: This suggests that individuals with asthma with low levels of CC16 combined with a history of Mp infection may be more susceptible to deficits in FEV1/FVC, the hallmark of airflow limitation, emphasizing the need for prospective studies designed to test this hypothesis.

Keywords: Asthma; CC16; Mycoplasma pneumoniae; lung function.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Clare Murray reports a relationship with AstraZeneca that includes: speaking and lecture fees. Clare Murray reports a relationship with Sanofi that includes: speaking and lecture fees. Clare Murray reports a relationship with GlaxoSmithKline that includes: speaking and lecture fees. Stefano Guerra and Julie Ledford are co-founders of a start-up, Aspiro Therapeutics, with the goal of developing novel CC16-based therapeutics. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Rava M, Tares L, Lavi I, Barreiro E, Zock JP, Ferrer A, Muniozguren N, Nadif R, Cazzoletti L, Kauffmann F, Anto JM, Guerra S, Serum levels of Clara cell secretory protein, asthma, and lung function in the adult general population, J Allergy Clin Immunol 132(1) (2013) 230–2. - PubMed
    1. Shijubo N, Itoh Y, Yamaguchi T, Shibuya Y, Morita Y, Hirasawa M, Okutani R, Kawai T, Abe S, Serum and BAL Clara cell 10 kDa protein (CC10) levels and CC10-positive bronchiolar cells are decreased in smokers, Eur Respir J 10(5) (1997) 1108–14. - PubMed
    1. Guerra S, Vasquez MM, Spangenberg A, Halonen M, Martin RJ, Club cell secretory protein in serum and bronchoalveolar lavage of patients with asthma, J Allergy Clin Immunol 138(3) (2016) 932–934.e1. - PMC - PubMed
    1. Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PM, Celli B, Coxson HO, Crim C, Lomas DA, MacNee W, Miller BE, Silverman EK, Tal-Singer R, Wouters E, Rennard SI, E. Investigators, Changes in forced expiratory volume in 1 second over time in COPD, N Engl J Med 365(13) (2011) 1184–92. - PubMed
    1. Lomas DA, Silver EK, Edwards LD, Miller BE, Coxson HO, Tal-Singer R, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort, Thorax 63(12) (2008) 1058–1063. - PubMed

MeSH terms